NCT05674058 (FIRSTORBIT) is a clinical trial of No intervention in Stargardt Disease, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT05674058?

NCT05674058 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT05674058?

Interventions in NCT05674058: No intervention.

What condition does NCT05674058 study?

NCT05674058 studies Stargardt Disease, Stargardt Disease 1, Fundus Flavimaculatus, Macular Degeneration, Stargardt, Macular Dystrophy With Flecks, Type 1.

Is NCT05674058 still recruiting?

NCT05674058 is currently active, enrolled. Last updated 22 April 2025.

Last reviewed 2025-04-22 · How we verify

NCT05674058: FIRSTORBIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Function and Imaging Assessments for G1961E-associated Stargardt Disease

Active, enrolled Last updated 22 April 2025

What this trial tests

trial testing No intervention in Stargardt Disease in 20 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 November 2022

Primary endpoint
31 October 2025

31 October 2025

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 November 2022
Primary completion	31 October 2025
Estimated completion	31 October 2025
Sites	1 location across Switzerland

Drugs / interventions tested

No intervention

Conditions studied

Stargardt Disease — all drugs for Stargardt Disease →
Stargardt Disease 1 — all drugs for Stargardt Disease 1 →
Fundus Flavimaculatus — all drugs for Fundus Flavimaculatus →
Macular Degeneration, Stargardt — all drugs for Macular Degeneration, Stargardt →

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Stargardt Disease or Stargardt Disease 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Some phenotypes of Stargardt disease are rather distinct. This includes the 'bull's eye maculopathy' phenotype associated with the frequent ABCA4 G1961E variant. In anticipation of a treatment trial, this natural history study aims to compare functional and structural outcome measures systematically.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Genetic Correlates of Phenotypic Variability in c.5882G>A p.(Gly1961Glu)-Associated Stargardt Disease.
Pas JAAH, Künzel SH, Ansari G, Pfau K, et al · · 2026 · PMID 41677386 · DOI 10.1167/iovs.67.2.32

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for Stargardt Disease

Currently open trials in the same condition.

NCT07266584 — Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration · NA · recruiting
NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting
NCT07439887 — Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients · Phase 1, PHASE2 · recruiting
NCT07417566 — A Study of DC6001 Tablet in Healthy Chinese Adult Subjects · Phase 1 · recruiting
NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05674058 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 22 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05674058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing